Key result
Treatment with miR-145 delivered via ultrasound-targeted microbubble destruction reduced the atherosclerotic plaque area by 48.04% compared with free miR-145 in vivo.
Why the study?
Seeking safe and effective gene delivery remains a key problem restricting the development of gene therapy for atherosclerosis.
Does UTMD-mediated delivery of miR-145 reduce atherosclerotic plaque formation in a mouse model?
Does UTMD-mediated delivery of miR-145 reduce atherosclerotic plaque formation in a mouse model?
Effect estimate: reduced by 48.04%
UTMD-mediated delivery of miR-145 significantly improves transfection efficiency and reduces atherosclerotic plaque area in a mouse model, suggesting a potential targeted gene therapy approach for atherosclerosis.
UTMD may enable safe miR-145 delivery to VSMCs in vitro; leaves open clinical translation for atherosclerosis.
Abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) play a key role in the formation and rupture of atherosclerotic plaques. Previous studies have confirmed that microRNA-145 (miR-145) is involved in the phenotypic regulation of VSMCs and reduction of atherosclerosis. At present, seeking safe and effective gene delivery remains a key problem restricting the development of gene therapy. In recent years, ultrasound-targeted microbubble destruction (UTMD) has become a safe and effective transfection method that is widely used in the basic research of gene therapy for heart and tumor diseases. Here, we synthesized cationic microbubbles to encapsulate miR-145 and targeted their release into VSMCs in vitro and in vivo using ultrasound. The feasibility of this gene therapy was verified by fluorescence microscopy and an in vivo imaging system. The results showed that treatment with miR-145 delivered via UTMD considerably improved the gene transfection efficiency and promoted the contraction phenotype of VSMCs in vitro . In vivo, this treatment reduced the atherosclerotic plaque area by 48.04% compared with treatment with free miR-145. Therefore, UTMD-mediated miRNA therapy may provide a new targeted therapeutic approach for atherosclerotic plaques.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2023) studied Atherosclerotic plaques. miR-145 delivered via ultrasound-targeted microbubble destruction (UTMD) vs. free miR-145 was evaluated on Atherosclerotic plaque area (reduced by 48.04%). Treatment with miR-145 delivered via ultrasound-targeted microbubble destruction reduced the atherosclerotic plaque area by 48.04% compared with free miR-145 in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: